1. Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens
- Author
-
Salvatore Del Prete, Eliel Bayever, Jayne Gurtler, Bart Michiels, Lori J. Goldstein, Vladimir Semiglazov, and Sergei Tjulandin
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Anthracycline ,Population ,Phases of clinical research ,Breast Neoplasms ,Dioxoles ,Neutropenia ,Gastroenterology ,Young Adult ,Breast cancer ,Tetrahydroisoquinolines ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Anthracyclines ,Prospective Studies ,Progression-free survival ,education ,Trabectedin ,Aged ,Neoplasm Staging ,Salvage Therapy ,education.field_of_study ,Taxane ,business.industry ,Carcinoma, Ductal, Breast ,Middle Aged ,Prognosis ,medicine.disease ,Surgery ,Survival Rate ,Carcinoma, Lobular ,Oncology ,Drug Resistance, Neoplasm ,Female ,Taxoids ,business ,Follow-Up Studies ,medicine.drug - Abstract
Background The purpose of this study was to assess the efficacy and safety of trabectedin for advanced breast cancer. Patients and Methods In an open-label, phase II, multicenter study, women with advanced breast cancer previously treated with ≤ 2 lines of chemotherapy for advanced disease, including both anthracyclines and taxanes, were randomized (1:1) to 3-hour infusions of trabectedin 1.3 mg/m2 once every 3 weeks (1/3 treatment arm) or 0.58 mg/m2 every week for 3 of 4 weeks (3/4 treatment arm). The primary end point was objective response. Secondary end points included time to progression (TTP), progression-free survival (PFS), and overall survival (OS). Results Fifty-two women (median age, 50 years; median chemotherapy agents, 4) were enrolled. Relative trabectedin dose intensities were 81% and 76% in the 1/3 and 3/4 treatment arms, respectively. Objective response rates were 12% (3 of 25) and 4% (1 of 27), respectively. Stable disease was observed in 14 (56%) and 11 (41%) patients in the 1/3 and 3/4 treatment arms, respectively, with median durations of 3.5 and 3.7 months. Median TTP and PFS were higher in the 1/3 treatment arm (3.1 months each) than in the 3/4 treatment arm (2.0 months each). At a median follow-up of 7 months in both treatment arms, median OS was not reached in the 1/3 treatment arm and was 9.4 months in the 3/4 treatment arm. The most frequent drug-related adverse events in the 1/3 and 3/4 treatment arms, respectively, were alanine aminotransferase (ALT) level increases (68% vs. 63%), nausea (56% vs. 59%), and asthenia (56% vs. 48%). Neutropenia and increases in ALT levels were the most frequent grade 3/4 events. Both types of events were usually transient and reversible. Conclusion In the population studied, trabectedin showed a manageable safety profile for both regimens analyzed. There were higher objective response rates and a longer PFS in the 1/3 treatment arm compared with the 3/4 treatment arm.
- Published
- 2014